drugset
drugset / Trial / NCT00450008

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

NCT00450008 ↗

Phase 2 Terminated 9 enrolled The Methodist Hospital Research Institute Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the relative efficacy and toxicity of combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA.

Timeline

Start
2006-12
Primary completion
2008-08
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Thalidomide Other / unclassified 200 mg Oral
Subject sargramostim Protein / enzyme biologic 250 ug/m2 Subcutaneous
Background Warfarin Small molecule 2.5 mg Oral

Indications

prostate neoplasm